KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash from Operations (2016 - 2025)

NovoCure's Cash from Operations history spans 12 years, with the latest figure at 18004000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 421.7% year-over-year to 18004000.0; the TTM value through Dec 2025 reached 49031000.0, down 85.94%, while the annual FY2025 figure was 49031000.0, 85.94% down from the prior year.
  • Cash from Operations for Q4 2025 was 18004000.0 at NovoCure, down from 20574000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 26172000.0 in Q2 2021 and bottomed at 35665000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 3569000.0 (2022), against an average of 1759600.0.
  • The largest annual shift saw Cash from Operations skyrocketed 808.53% in 2021 before it plummeted 826.51% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 14404000.0 in 2021, then tumbled by 125.74% to 3707000.0 in 2022, then plummeted by 292.72% to 14558000.0 in 2023, then soared by 76.29% to 3451000.0 in 2024, then crashed by 421.7% to 18004000.0 in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Cash from Operations are 18004000.0 (Q4 2025), 20574000.0 (Q3 2025), and 15936000.0 (Q2 2025).